Egetis Therapeutics AB (LTS:0ABW) Beta: -0.2027 (As of Jun. 26, 2026)


LTS:0ABW Egetis Therapeutics AB LTS:0ABW
60 GF Score
Price kr6.19
GF Value kr5.59
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Beta?

Egetis Therapeutics AB LTS:0ABW +14.84% 60 Beta is -0.2027 as of Jun. 26, 2026. GuruFocus rates LTS:0ABW with a GF Score™ of 60/100 and a GF Value™ of kr5.59 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Egetis Therapeutics AB's Beta is -0.2027.


Egetis Therapeutics AB  (LTS:0ABW) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Egetis Therapeutics AB Beta Related Terms


Egetis Therapeutics AB Beta Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Beta Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.21

Egetis Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1.21 0.71

LTS:0ABW vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Beta distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Beta falls into.


LTS:0ABW
60GF Score
Egetis Therapeutics AB LTS:0ABW
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egetis Therapeutics AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.2027 mean?
Egetis Therapeutics AB (LTS:0ABW) has a Beta of -0.2027 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Egetis Therapeutics AB and its competitors.
Is Egetis Therapeutics AB's Beta too high?
Egetis Therapeutics AB's current Beta is -0.2027. Overall, Egetis Therapeutics AB has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Beta compare to VRTX and REGN?
Egetis Therapeutics AB's Beta of -0.2027 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Beta is -0.2027. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (LTS:0ABW) is currently considered Modestly Overvalued. The stock's GF Value™ is kr5.59, compared to a current price of kr6.19 — trading 10.7% above its estimated fair value. The current Beta is -0.2027. Egetis Therapeutics AB's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Egetis Therapeutics AB (LTS:0ABW), the current Beta is -0.2027 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr6.19 is trading 10.7% above its estimated GF Value™ of kr5.59. GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.

Key valuation signals for LTS:0ABW:

  • Beta: -0.2027
  • GF Value™: kr5.59 vs. price of kr6.19 (10.7% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
60GF Score

Get the complete analysis for LTS:0ABW

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.19
Price
kr5.59
GF Value